<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "9: expenses will increase", fill: "#7b68ee"},
{source: "9: expenses will increase", target: "9: continue development", fill: "#7b68ee"},
{source: "9: continue development", target: "9: potential products seek", fill: "#7b68ee"},
{source: "9: potential products seek", target: "9: necessary regulatory approvals", fill: "#7b68ee"},
{source: "9: necessary regulatory approvals", target: "9: manufacture", fill: "#7b68ee"},
{source: "9: manufacture", target: "9: candidates", fill: "#7b68ee"},
{source: "9: expenses will increase", target: "10: Directly ", fill: "#f8f8ff"},
{source: "10: Directly ", target: "10: Lilly ICOS ", fill: "#f8f8ff"},
{source: "10: Lilly ICOS ", target: "10: commercializing", fill: "#f8f8ff"},
{source: "10: Directly ", target: "11: Furthermore Lilly ICOS ", fill: "#e9967a"},
{source: "11: Furthermore Lilly ICOS ", target: "11: demonstrating safety", fill: "#e9967a"},
{source: "11: demonstrating safety", target: "11: seeking regulatory approvals", fill: "#e9967a"},
{source: "11: seeking regulatory approvals", target: "11: market tadalafil", fill: "#e9967a"},
{source: "11: market tadalafil", target: "11: indications", fill: "#e9967a"},
{source: "11: Furthermore Lilly ICOS ", target: "28: Subsequently ", fill: "#f0f8ff"},
{source: "28: Subsequently ", target: "28: media attention", fill: "#f0f8ff"},
{source: "28: media attention", target: "28: possible connection", fill: "#f0f8ff"},
{source: "28: possible connection", target: "28: between use", fill: "#f0f8ff"},
{source: "28: between use", target: "28: sildenafil citrate", fill: "#f0f8ff"},
{source: "28: sildenafil citrate", target: "28: erectile dysfunction", fill: "#f0f8ff"},
{source: "28: erectile dysfunction", target: "28: development", fill: "#f0f8ff"},
{source: "28: development", target: "28: nonarteritic", fill: "#f0f8ff"},
{source: "28: nonarteritic", target: "28: anterior ischemic optic neuropathy", fill: "#f0f8ff"},
{source: "28: anterior ischemic optic neuropathy", target: "28: impairment", fill: "#f0f8ff"},
{source: "28: impairment", target: "28: blindness", fill: "#f0f8ff"},
{source: "28: Subsequently ", target: "42: risks with respect", fill: "#d9004c"},
{source: "42: risks with respect", target: "42: new product candidates", fill: "#d9004c"},
{source: "42: new product candidates", target: "42: commercialize ie", fill: "#d9004c"},
{source: "42: commercialize ie", target: "42: third party", fill: "#d9004c"},
{source: "42: third party", target: "42: marketing sales", fill: "#d9004c"},
{source: "42: marketing sales", target: "42: distribution capabilities necessary", fill: "#d9004c"},
{source: "42: distribution capabilities necessary", target: "42: successfully", fill: "#d9004c"},
{source: "42: successfully", target: "42: commercialize new products", fill: "#d9004c"},
{source: "42: risks with respect", target: "46: compete successfully", fill: "#880085"},
{source: "46: compete successfully", target: "46: pharmaceutical", fill: "#880085"},
{source: "46: pharmaceutical", target: "46: biotechnological products", fill: "#880085"},
{source: "46: compete successfully", target: "56: Korea in November ", fill: "#008000"},
{source: "56: Korea in November ", target: "56: investigational new drug", fill: "#008000"},
{source: "56: investigational new drug", target: "56: application", fill: "#008000"},
{source: "56: application", target: "56: been filed with", fill: "#008000"},
{source: "56: been filed with", target: "56: FDA Other ", fill: "#008000"},
{source: "56: FDA Other ", target: "56: erectile dysfunction treatments", fill: "#008000"},
{source: "56: erectile dysfunction treatments", target: "56: development", fill: "#008000"},
{source: "56: development", target: "56: technologies", fill: "#008000"},
{source: "56: technologies", target: "56: indirectly successful", fill: "#008000"},
{source: "56: indirectly successful", target: "56: erectile dysfunction could negatively impact", fill: "#008000"},
{source: "56: Korea in November ", target: "60: competitors", fill: "#dcd0ff"},
{source: "60: competitors", target: "60: effective", fill: "#dcd0ff"},
{source: "60: effective", target: "60: future products", fill: "#dcd0ff"},
{source: "60: future products", target: "60: products obsolete", fill: "#dcd0ff"},
{source: "60: products obsolete", target: "60: regulatory approvals", fill: "#dcd0ff"},
{source: "60: regulatory approvals", target: "60: rapidly than", fill: "#dcd0ff"},
{source: "60: rapidly than", target: "60: with labeling", fill: "#dcd0ff"},
{source: "60: with labeling", target: "60: than ours which would reduce", fill: "#dcd0ff"},
{source: "60: than ours which would reduce", target: "60: potential sales", fill: "#dcd0ff"},
{source: "60: potential sales", target: "60: candidates", fill: "#dcd0ff"},
{source: "60: candidates", target: "60: intellectual property rights", fill: "#dcd0ff"},
{source: "60: intellectual property rights", target: "60: could increase", fill: "#dcd0ff"},
{source: "60: could increase", target: "60: prevent development", fill: "#dcd0ff"},
{source: "60: prevent development", target: "60: commercialization", fill: "#dcd0ff"},
{source: "60: commercialization", target: "60: product candidates", fill: "#dcd0ff"},
{source: "60: product candidates", target: "60: devote greater resources", fill: "#dcd0ff"},
{source: "60: devote greater resources", target: "60: new technologies", fill: "#dcd0ff"},
{source: "60: new technologies", target: "60: scientific advances", fill: "#dcd0ff"},
{source: "60: scientific advances", target: "60: price competition", fill: "#dcd0ff"},
{source: "60: price competition", target: "60: successfully", fill: "#dcd0ff"},
{source: "60: successfully", target: "60: greater success", fill: "#dcd0ff"},
{source: "60: greater success", target: "60: recruiting skilled workers from", fill: "#dcd0ff"},
{source: "60: recruiting skilled workers from", target: "60: available talent", fill: "#dcd0ff"},
{source: "60: available talent", target: "60: collaborative", fill: "#dcd0ff"},
{source: "60: collaborative", target: "60: arrangements", fill: "#dcd0ff"},
{source: "60: arrangements", target: "60: acquisition", fill: "#dcd0ff"},
{source: "60: acquisition", target: "60: opportunities", fill: "#dcd0ff"},
{source: "60: opportunities", target: "60: readily than", fill: "#dcd0ff"},
{source: "60: competitors", target: "66: potential product candidates", fill: "#967bb6"},
{source: "66: potential product candidates", target: "66: clinical testing", fill: "#967bb6"},
{source: "66: clinical testing", target: "66: demonstrate", fill: "#967bb6"},
{source: "66: demonstrate", target: "66: regulatory approval", fill: "#967bb6"},
{source: "66: regulatory approval", target: "66: such products", fill: "#967bb6"},
{source: "66: potential product candidates", target: "68: preclinical tests", fill: "#a76bcf"},
{source: "68: preclinical tests", target: "68: clinical studies", fill: "#a76bcf"},
{source: "68: clinical studies", target: "68: Contents ", fill: "#a76bcf"},
{source: "68: Contents ", target: "68: candidates under development", fill: "#a76bcf"},
{source: "68: candidates under development", target: "68: studies may", fill: "#a76bcf"},
{source: "68: studies may", target: "68: demonstrate", fill: "#a76bcf"},
{source: "68: demonstrate", target: "68: such product candidates", fill: "#a76bcf"},
{source: "68: such product candidates", target: "68: extent necessary", fill: "#a76bcf"},
{source: "68: extent necessary", target: "68: regulatory approvals", fill: "#a76bcf"},
{source: "68: regulatory approvals", target: "68: commercialization", fill: "#a76bcf"},
{source: "68: commercialization", target: "68: product candidates worthwhile", fill: "#a76bcf"},
{source: "68: preclinical tests", target: "START_HERE", fill: "#a76bcf"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Bombings</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gobelins_Manufactory">Gobelins Manufactory</a></td>
      <td>The Gobelins Manufactory (French: Manufacture des Gobelins) is a historic tapestry factory in Paris, France. It is located at 42 avenue des Gobelins, near Les Gobelins métro station in the 13th arrondissement of Paris.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Build-on-demand">Build-on-demand</a></td>
      <td>Build-on-demand or manufacturing on demand (MOD) refers to a manufacturing process where goods are produced only when or as they are required. This allows scalability and adjustable assemblies depending on the current needs of the part requestor or client.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Computer-aided_manufacturing">Computer-aided manufacturing</a></td>
      <td>Computer-aided manufacturing (CAM) also known as computer-aided modeling or computer-aided machining is the use of software to control machine tools in the manufacturing of work pieces. This is not the only definition for CAM, but it is the most common; CAM may also refer to the use of a computer to assist in all operations of a manufacturing plant, including planning, management, transportation and storage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tadalafil">Tadalafil</a></td>
      <td>Tadalafil, sold under the brand name Cialis among others, is a medication used to treat erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension. It is a tablet taken by mouth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Icos">Icos</a></td>
      <td>Ice is water frozen into a solid state, typically forming at or below temperatures of 0 degrees Celsius or 32 degrees Fahrenheit. Depending on the presence of impurities such as particles of soil or bubbles of air, it can appear transparent or a more or less opaque bluish-white color.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/George_Rathmann">George Rathmann</a></td>
      <td>George Blatz Rathmann  (1927–2012) was an American chemist, biologist, pioneer in biotechnology and corporate executive. In 1980 he co-founded and served as the first CEO of Amgen, and later founded Icos.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Christopher_Henney">Christopher Henney</a></td>
      <td>Christopher Henney is a British-American biotechnology company executive and board member. In 1980, he co-founded  Immunex Corp., which was later acquired by Amgen Inc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sildenafil">Sildenafil</a></td>
      <td>Sildenafil, sold under the brand name Viagra among others, is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is unclear if it is effective for treating sexual dysfunction in women.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medication">Medication</a></td>
      <td>Meditation is a practice in which an individual uses a technique – such as mindfulness, or focusing the mind on a particular object, thought, or activity – to train attention and awareness, and achieve a mentally clear and emotionally calm and stable state.Meditation  is practiced in numerous religious traditions. The earliest records of meditation (dhyana) are found in the Upanishads of Hindu philosophy, and meditation plays a salient role in the contemplative repertoire of Buddhism and Hinduism.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutics">Pharmaceutics</a></td>
      <td>Pharmaceutics is the discipline of pharmacy that deals with the process of turning a new chemical entity (NCE) or old drugs into a medication to be used safely and effectively by patients.  It is also called the science of dosage form design.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmacy">Pharmacy</a></td>
      <td>Pharmacy is the clinical health science that links medical science with chemistry and it is charged with the discovery, production, disposal, safe and effective use, and control of medications and drugs. The practice of pharmacy requires excellent knowledge of drugs, their mechanism of action, side effects, interactions, mobility and toxicity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Teva_Pharmaceuticals">Teva Pharmaceuticals</a></td>
      <td>Teva Pharmaceutical Industries Ltd. (also known as Teva Pharmaceuticals) is an Israeli multinational pharmaceutical company with headquarters in Petah Tikva, Israel.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_code">Pharmaceutical code</a></td>
      <td>Pharmaceutical codes are used in medical classification to uniquely identify medication. They may uniquely identify an active ingredient, drug system (including inactive ingredients and time-release agents) in general, or a specific pharmaceutical product from a specific manufacturer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_manufacturing">Pharmaceutical manufacturing</a></td>
      <td>Pharmaceutical manufacturing is the process of industrial-scale synthesis of pharmaceutical drugs as part of the pharmaceutical industry.  The process of drug manufacturing can be broken down into a series of unit operations, such as milling, granulation, coating, tablet pressing, and others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmacology">Pharmacology</a></td>
      <td>Pharmacology is a branch of medicine, biology and pharmaceutical sciences concerned with drug or medication action, where a drug may be defined as any artificial, natural, or endogenous (from within the body) molecule which exerts a biochemical or physiological effect on the cell, tissue, organ, or organism (sometimes the word pharmacon is used as a term to encompass these endogenous and exogenous bioactive species). More specifically, it is the study of the interactions that occur between a living organism and chemicals that affect normal or abnormal biochemical function.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_research">Clinical research</a></td>
      <td>Clinical research is a branch of healthcare science that determines the safety and effectiveness (efficacy) of medications, devices, diagnostic products and treatment regimens intended for human use. These may be used for prevention, treatment, diagnosis or for relieving symptoms of a disease.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bavarian_Nordic">Bavarian Nordic</a></td>
      <td>Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicago_Inc.">Medicago Inc.</a></td>
      <td>Medicago Inc. is a privately-owned Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preclinical_development">Preclinical development</a></td>
      <td>In drug development, preclinical development, also termed preclinical studies or nonclinical studies, is a stage of research that begins before clinical trials (testing in humans) and during which important feasibility, iterative testing and drug safety data are collected, typically in laboratory animals.\nThe main goals of preclinical studies are to determine a starting, safe dose for first-in-human study and assess potential toxicity of the product, which typically include new medical devices, prescription drugs, and diagnostics.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_study_report">Clinical study report</a></td>
      <td>In medicine, a clinical study report (CSR) on a clinical trial is a document, typically very long, providing much detail about the methods and results of a trial. A CSR is a scientific document addressing efficacy and safety, not a sales or marketing tool; its content is similar to that of a peer-reviewed academic paper.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Neutron_capture_therapy_of_cancer">Neutron capture therapy of cancer</a></td>
      <td>Neutron capture therapy (NCT) is a radio-therapeutic modality for treating locally invasive malignant tumors such as primary brain tumors, recurrent cancers of the head and neck region, and cutaneous and extracutaneous melanomas. It is a two-step procedure: first, the patient is injected with a tumor-localizing drug containing the non-radioactive isotope boron-10 (10B), which has a high propensity to capture low energy "thermal" neutrons.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Epitalon">Epitalon</a></td>
      <td>Epitalon is a synthetic peptide, telomerase activator, and putative anti-aging drug developed by the St. Petersburg Institute of Bioregulation and Gerontology, which was identified as the putative active component of a bovine pineal gland extract known as epithalamin.Most studies on epitalon and epithalamin have been conducted by the St.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Effects_of_meditation">Effects of meditation</a></td>
      <td>The psychological and physiological effects of meditation have been studied. In recent years, studies of meditation have increasingly involved the use of modern instruments, such as fMRI and EEG, which are able to observe brain physiology and neural activity in living subjects, either during the act of meditation itself or before and after meditation.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ICOS CORP      Item 1A   Risk Factors          ICOS  operates  in  an <font color="blue">environment</font> that involves a number of risks and     <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>The risks and <font color="blue">uncertainties</font> described below are not the only     risks and <font color="blue">uncertainties</font> we face</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks and <font color="blue">uncertainties</font> not     <font color="blue">presently known</font> to us or that are not considered material, and therefore not     mentioned  herein,  may  impair our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If any of the     following  risks  actually  occur, our business, operating results and     <font color="blue">financial position could</font> be harmed</td>
    </tr>
    <tr>
      <td>Risks Related to Our Business          We have a history of losses and may be unable to <font color="blue">sustain <font color="blue">profitability</font></font></td>
    </tr>
    <tr>
      <td>We have incurred significant operating <font color="blue">losses since</font> we began <font color="blue">operations</font> in     1990</td>
    </tr>
    <tr>
      <td><font color="blue">As of December </font>31, 2005, we had an <font color="blue">accumulated deficit</font> of dlra862dtta6     million</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will be able to achieve or increase     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We anticipate that operating <font color="blue">expenses will increase</font> in the     future as we <font color="blue">continue <font color="blue">development</font></font> of our <font color="blue">potential products</font>, seek to obtain     <font color="blue"><font color="blue">necessary</font> <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font></font> and <font color="blue">manufacture</font> and market these product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Directly, and through Lilly ICOS, we expect to continue to incur     substantial marketing and other expenses related to <font color="blue">commercializing</font> <font color="blue">Cialis  </font>   in the United States, Europe, Mexico and Canada</td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">Lilly ICOS </font>may     incur significant expenses in <font color="blue">demonstrating safety</font> and efficacy in order to     provide a basis for <font color="blue">seeking <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font></font> to <font color="blue">market tadalafil</font> in new     <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Lilly ICOS </font>and/or ICOS may be unable to <font color="blue">generate sufficient</font>     revenues  from  <font color="blue">Cialis  </font>and  other  products  to  achieve and maintain     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Overall changes in market demand for <font color="blue">erectile dysfunction</font>     drugs, and Lilly ICOS’ ability to capture and retain market share, will     <font color="blue">significantly affect revenues</font> and expected <font color="blue">profitability</font> from Cialis and, in     turn, our results of <font color="blue">operations</font> and <font color="blue">cash flows</font></td>
    </tr>
    <tr>
      <td>For example, in 2005, the     overall US market of PDE5 <font color="blue">inhibitor prescriptions</font>, for the treatment of     <font color="blue">erectile dysfunction</font>, is estimated to have declined by approximately 3dtta2prca,     compared to 2004</td>
    </tr>
    <tr>
      <td>13     ______________________________________________________________________    [33]Table of <font color="blue">Contents       </font>Our operating results are subject to <font color="blue">fluctuations</font> that may cause our stock     price to decline</td>
    </tr>
    <tr>
      <td>Our revenue and other income are unpredictable and     <font color="blue">may fluctuate due</font> to many factors, some of which we <font color="blue">cannot control</font></td>
    </tr>
    <tr>
      <td>For     example, factors affecting our revenue and other income, as well as <font color="blue">Lilly     </font>ICOS’ revenue, presently or in the future, could include:           •   level of demand for our products, including changes in physician     <font color="blue">prescribing habits</font>, and <font color="blue">unfavorable publicity concerning</font> our products or     similar products;           •   changes in <font color="blue">wholesaler buying patterns</font>;           •   changes in <font color="blue">reimbursement rates</font> or policies;           •   timing of non-recurring license fees and the <font color="blue">achievement</font> of <font color="blue">milestones</font>     <font color="blue">under license</font> and <font color="blue"><font color="blue">collaborative</font> <font color="blue">agreement</font>s</font>;           •   <font color="blue">government regulation</font>, including <font color="blue">regulations</font> related to the marketing     of our products;           •   <font color="blue">increased competition</font> for new or <font color="blue">existing products</font>;           •   timing and success of <font color="blue">product launches</font>;           •   level of our <font color="blue">contract <font color="blue">manufacturing</font></font> for <font color="blue">third parties</font>;           •   <font color="blue">fluctuations</font> in <font color="blue">foreign currency exchange rates</font>;           •   changes in our product marketing, selling and <font color="blue">pricing strategies</font> and     programs; and           •   <font color="blue">inability</font> to <font color="blue">provide adequate supply</font> of our products</td>
    </tr>
    <tr>
      <td>In addition, our expenses, including <font color="blue">payments owed by us under licensing</font> or     <font color="blue"><font color="blue">collaborative</font> <font color="blue">arrangements</font></font>, are unpredictable and <font color="blue">may fluctuate from quarter</font>     to quarter</td>
    </tr>
    <tr>
      <td>We believe that quarter to <font color="blue">quarter comparisons</font> of our operating     results are not a good indicator of our <font color="blue">future performance</font> and should not be     <font color="blue">relied upon</font> to predict our <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>It is possible that, in the     future, our operating results in a <font color="blue">particular quarter</font> or <font color="blue">quarters will</font> not     meet the <font color="blue">expectations</font> of <font color="blue">securities analysts</font> or investors, causing the     <font color="blue">market price</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>Even though Cialis has been approved for <font color="blue">commercial sale</font>, if we or others     identify <font color="blue">additional</font> side effects, approval could be withdrawn or sales of     Cialis could be <font color="blue">significantly reduced</font></td>
    </tr>
    <tr>
      <td>If  we  or others identify <font color="blue">additional</font> or potential side effects, or if     <font color="blue"><font color="blue">manufacturing</font> problems</font> occur:           •   we may take Cialis off the market;           •   <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font> may</font> be withdrawn or other <font color="blue"><font color="blue">regulatory</font> sanctions may</font>     be imposed;           •   <font color="blue">reformulation</font> of the product, <font color="blue">additional</font> <font color="blue">clinical studies</font>, and/or     changes in labeling of the <font color="blue">product may</font> be required;           •   changes to or re-approvals of our or our partner’s <font color="blue">manufacturing</font>     <font color="blue"><font color="blue">facilities</font> may</font> be required;           •   our reputation in the <font color="blue">marketplace may suffer</font>; and           •   lawsuits, including class action suits, may be <font color="blue">brought against us</font></td>
    </tr>
    <tr>
      <td>14     ______________________________________________________________________    [34]Table of <font color="blue">Contents       </font>The <font color="blue">identification</font> of <font color="blue">additional</font> or potential side effects, and subsequent     consequences, could harm or <font color="blue">prevent sales</font> <font color="blue">of Cialis </font>or <font color="blue">could increase</font> the     costs and expenses of <font color="blue">commercializing</font> and marketing Cialis</td>
    </tr>
    <tr>
      <td>General post-marketing surveillance of our product is ongoing, as well as     <font color="blue">specific studies</font> that are required as part of our <font color="blue">marketing approvals</font> in     various  <font color="blue">jurisdictions</font></td>
    </tr>
    <tr>
      <td>Either  of  these sources could result in the     <font color="blue">identification</font> of new or potential side effects</td>
    </tr>
    <tr>
      <td>For example, in May 2005,     <font color="blue">Lilly ICOS </font>added certain vision-related adverse events to the label for     Cialis, <font color="blue">based on</font> reports from post-marketing surveillance</td>
    </tr>
    <tr>
      <td>Subsequently,     there  was substantial <font color="blue">media attention</font> regarding a <font color="blue">possible connection</font>     <font color="blue">between use</font> of Viagra^® (<font color="blue">sildenafil citrate</font>), another PDE5 inhibitor for the     treatment of <font color="blue">erectile dysfunction</font>, and the <font color="blue">development</font> of non-arteritic     <font color="blue">anterior ischemic optic neuropathy</font> (NAION), a condition that may lead to     permanent visual <font color="blue">impairment</font> or <font color="blue">blindness</font></td>
    </tr>
    <tr>
      <td>In July 2005, the FDA issued a     <font color="blue">statement indicating</font> that information regarding reports of NAION in patients     using PDE5 <font color="blue">inhibitors</font> had been added to the labels of all products in the     PDE5 inhibitor class, including Cialis</td>
    </tr>
    <tr>
      <td>The FDA statement and the relevant     <font color="blue">label language</font> state that a <font color="blue">causal <font color="blue">relationship</font> between</font> the <font color="blue">development</font> of     NAION  and  use of these drugs has not been established</td>
    </tr>
    <tr>
      <td>Such a causal     <font color="blue">relationship</font> could be established in the future</td>
    </tr>
    <tr>
      <td>Adverse <font color="blue">media attention</font> and     concerns related to side <font color="blue">effects may reduce sales</font> of Cialis</td>
    </tr>
    <tr>
      <td>The success <font color="blue">of Cialis </font>depends, in large part, on the promotion, sales and     <font color="blue">marketing <font color="blue">activities</font></font> of our partner, Lilly</td>
    </tr>
    <tr>
      <td>Similarly, the success of our     <font color="blue">potential products</font> in <font color="blue">development</font> could depend on our ability to arrange     assistance from <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Through Lilly ICOS, we and Lilly have <font color="blue">joint responsibility</font> for the promotion     and sale of <font color="blue">Cialis in North America and Europe</font></td>
    </tr>
    <tr>
      <td>Lilly has rights to <font color="blue">Cialis  </font>   for the other parts of the world, with royalties to be paid to <font color="blue">Lilly ICOS </font>    We believe that the efforts of a <font color="blue">sizeable <font color="blue">pharmaceutical</font> sales force</font> and     experienced <font color="blue">marketing staff</font> are important to the <font color="blue">continued success</font> of the     product</td>
    </tr>
    <tr>
      <td>We have relied, and expect to continue to rely, heavily on <font color="blue">Lilly     </font>for promotion, sales and marketing of Cialis, <font color="blue">even <font color="blue">with respect</font></font> to our joint     <font color="blue">responsibilities</font></td>
    </tr>
    <tr>
      <td>We have limited staff and experience in these areas, and     we  may  or  may  not  be  capable  of  <font color="blue">independently</font>  fulfilling  our     <font color="blue">responsibilities</font></td>
    </tr>
    <tr>
      <td><font color="blue">We and Lilly </font><font color="blue">may also rely on contract sales <font color="blue">organizations</font></font>     to perform <font color="blue">sales <font color="blue">activities</font></font> for Cialis</td>
    </tr>
    <tr>
      <td>If  Lilly fails to <font color="blue">devote appropriate resources</font> to promotion and sales     <font color="blue">activities</font>, sales <font color="blue">of Cialis </font>could be reduced or could fail to reach their     full potential</td>
    </tr>
    <tr>
      <td>In addition, if Lilly breaches or terminates its <font color="blue">agreement</font>     with us, or <font color="blue"><font color="blue">otherwise fail</font>s</font> to conduct its <font color="blue">activities</font> related to Cialis in     an <font color="blue">effective</font> or <font color="blue">timely manner</font>, sales <font color="blue">of Cialis </font>could be delayed, reduced or     <font color="blue">become <font color="blue">substantially</font></font> more costly for us to achieve</td>
    </tr>
    <tr>
      <td>We will face similar     <font color="blue">risks <font color="blue">with respect</font></font> to new product <font color="blue">candidates</font> that we <font color="blue">commercialize</font> (ie,     without the assistance of a <font color="blue">third party</font>, we may be unable to establish     marketing, sales and <font color="blue"><font color="blue">distribution</font> capabilities <font color="blue">necessary</font></font> to <font color="blue">successfully</font>     <font color="blue"><font color="blue">commercialize</font> new products</font>)</td>
    </tr>
    <tr>
      <td>Co-promotion or other <font color="blue">marketing <font color="blue">arrangements</font></font>     <font color="blue">with others may</font> be needed to <font color="blue">commercialize</font> our <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>However,     these <font color="blue"><font color="blue">arrangements</font> could significantly limit</font> the revenues we <font color="blue">derive from</font>     these  potential  products and <font color="blue">increase associated</font> operating expenses</td>
    </tr>
    <tr>
      <td>Additionally, these <font color="blue">parties may fail</font> to <font color="blue">commercialize</font> our <font color="blue">potential products</font>     <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>We may be unable to compete <font color="blue">successfully</font> in the markets for <font color="blue">pharmaceutical</font>     and <font color="blue">biotechnological products</font></td>
    </tr>
    <tr>
      <td>The  markets  in  which  we compete are <font color="blue">well established</font> and intensely     <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>We may be unable to compete <font color="blue">successfully</font> against our current     and <font color="blue">future <font color="blue">competitors</font></font></td>
    </tr>
    <tr>
      <td>Our failure to compete <font color="blue">successfully</font> may result in     pricing  <font color="blue">reductions</font>,  reduced gross margins, failure to achieve market     <font color="blue">acceptance</font>  for  our  products,  and  an  <font color="blue">inability</font> to achieve or grow     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Cialis and our <font color="blue">potential products</font>, if approved and <font color="blue">commercialize</font>d, compete     or will compete against <font color="blue">well established</font> existing <font color="blue">therapeutic</font> products or     <font color="blue">treatments</font></td>
    </tr>
    <tr>
      <td><font color="blue">successfully</font> <font color="blue">commercialize</font>d Viagra^®     (<font color="blue">sildenafil citrate</font>), a PDE5 inhibitor that <font color="blue">competes with</font> our product,     Cialis</td>
    </tr>
    <tr>
      <td>GlaxoSmithKline  and Bayer AG, outside the United States, and     GlaxoSmithKline and Schering-Plough Corporation, in the United States, are     marketing Levitra^® (vardenafil HCl), a third PDE5 inhibitor</td>
    </tr>
    <tr>
      <td>Pfizer, Bayer     AG, GlaxoSmithKline and Schering-Plough have invested substantial resources     in marketing their PDE5 <font color="blue">inhibitor products</font>, and we would anticipate                                           15     ______________________________________________________________________    [35]Table of <font color="blue">Contents       </font>that they <font color="blue">would continue efforts</font> to <font color="blue">aggressively compete</font> in this market</td>
    </tr>
    <tr>
      <td>In     addition,  a  number of <font color="blue">pharmaceutical</font> and <font color="blue"><font color="blue">bio<font color="blue">technology</font></font> companies</font> are     currently developing <font color="blue">new products targeting</font> the <font color="blue">same diseases</font> and medical     <font color="blue">conditions</font> that we target</td>
    </tr>
    <tr>
      <td>Another PDE5 inhibitor, Zydena, was approved for     marketing  in  <font color="blue">Korea in November </font>2005, and an <font color="blue">investigational new drug</font>     <font color="blue">application</font> related to this product has <font color="blue">been filed with</font> the <font color="blue">FDA Other     </font><font color="blue">erectile dysfunction</font> <font color="blue">treatments</font> are in <font color="blue">development</font>, and any other products     or <font color="blue">technologies</font> that are directly or <font color="blue">indirectly successful</font> in treating     <font color="blue">erectile dysfunction</font> could negatively impact the market for Cialis</td>
    </tr>
    <tr>
      <td>If a     PDE5 inhibitor with a time of <font color="blue">effective</font>ness comparable to or <font color="blue">longer than</font>     that <font color="blue">of Cialis </font>or a generic PDE5 inhibitor is <font color="blue">successfully</font> <font color="blue">commercialize</font>d,     it might have a <font color="blue">significant adverse</font> effect on the market for Cialis</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> include <font color="blue">pharmaceutical</font> companies, <font color="blue"><font color="blue">bio<font color="blue">technology</font></font> companies</font>,     academic and <font color="blue">research institutions</font> and <font color="blue">government agencies</font></td>
    </tr>
    <tr>
      <td>Many of these     <font color="blue">organizations</font>, including those who market PDE5 <font color="blue">inhibitors</font> that <font color="blue">compete with</font>     Cialis, have <font color="blue">substantially</font> more experience and more capital, research and     <font color="blue">development</font>, <font color="blue">regulatory</font>, <font color="blue">manufacturing</font>, sales, marketing, human and other     <font color="blue">resources than</font> we do</td>
    </tr>
    <tr>
      <td>As a result, our <font color="blue">competitors</font> may:           •   develop products that are safer, more <font color="blue">effective</font> or less costly than     any of our current or <font color="blue">future products</font> or that render our <font color="blue">products obsolete</font>;           •   obtain FDA and other <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> or reach the market with     their products more <font color="blue">rapidly than</font> we can or <font color="blue">with labeling</font> claims more     favorable than ours, which would reduce the <font color="blue">potential sales</font> of our product     <font color="blue">candidates</font>;           •   obtain <font color="blue">intellectual property rights</font> that <font color="blue">could increase</font> our costs or     prevent <font color="blue">development</font> or <font color="blue">commercialization</font> of our product <font color="blue">candidates</font>;           •   <font color="blue">devote greater resources</font> to market or sell their products;           •   adapt more quickly to new <font color="blue">technologies</font> and <font color="blue">scientific advances</font>;           •   initiate or withstand substantial <font color="blue">price competition</font> more <font color="blue">successfully</font>     than we can;           •   have <font color="blue">greater success</font> in <font color="blue">recruiting skilled workers from</font> the limited     pool of <font color="blue">available talent</font>;           •   more <font color="blue">effective</font>ly negotiate third-party licensing and <font color="blue">collaborative</font>     <font color="blue">arrangements</font>; and           •   take advantage of <font color="blue">acquisition</font> or other <font color="blue">opportunities</font> more <font color="blue">readily than</font>     we can</td>
    </tr>
    <tr>
      <td>We face, and <font color="blue">will continue</font> to face, intense competition from other companies     for  <font color="blue">collaborative</font>  <font color="blue">arrangements</font> with <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font>     companies, for <font color="blue">relationship</font>s with academic and <font color="blue">research institutions</font>, and     for  licenses  to products and <font color="blue">proprietary <font color="blue">technology</font></font></td>
    </tr>
    <tr>
      <td>In addition, we     anticipate that we will face <font color="blue">increased competition</font> in the <font color="blue">future as new</font>     <font color="blue">companies enter</font> our markets and as scientific <font color="blue">development</font>s surrounding     protein-based and small molecule <font color="blue">therapeutic</font>s continue to <font color="blue">accelerate</font></td>
    </tr>
    <tr>
      <td>The successful <font color="blue">development</font> of new <font color="blue">therapeutic</font> products is complex and takes     a long time, and our <font color="blue">efforts may</font> not result in <font color="blue"><font color="blue">commercial product</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Successful </font><font color="blue">development</font> of <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> products is     <font color="blue">highly uncertain</font>, and very few research and <font color="blue">development</font> projects produce a     <font color="blue">commercial product</font></td>
    </tr>
    <tr>
      <td>Any failure or substantial delay in completing clinical     trials for our product <font color="blue">candidates</font> may severely harm our business</td>
    </tr>
    <tr>
      <td>We must     subject  our potential product <font color="blue">candidates</font> to extensive preclinical and     <font color="blue">clinical testing</font> to <font color="blue">demonstrate</font> their safety and efficacy for humans before     obtaining <font color="blue"><font color="blue">regulatory</font> approval</font> for the sale of any of <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Clinical     </font>studies are expensive, time-consuming and may take years to complete</td>
    </tr>
    <tr>
      <td>We may     not complete <font color="blue">preclinical tests</font> and <font color="blue">clinical studies</font> of product                                           16     ______________________________________________________________________    [36]Table of <font color="blue">Contents       </font><font color="blue">candidates</font> under <font color="blue">development</font>, and the results of the tests and <font color="blue">studies may</font>     fail to <font color="blue">demonstrate</font> the safety or efficacy of such product <font color="blue">candidates</font> to the     <font color="blue">extent <font color="blue">necessary</font></font> to obtain <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> or to make <font color="blue">commercialization</font>     of the product <font color="blue">candidates</font> worthwhile</td>
    </tr>
    <tr>
      <td>At any time during these clinical     studies, factors such as in<font color="blue">effective</font>ness of the <font color="blue">product candidate</font>, discovery     of  unacceptable  toxicities  or  side effects, <font color="blue">development</font> of disease     resistance or other <font color="blue">physiological factors</font>, or delays in <font color="blue">patient enrollment</font>,     could cause us to interrupt, limit, delay or abort the <font color="blue">development</font> of these     product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>In addition, success in preclinical and early <font color="blue">clinical studies</font> does not     ensure that late-stage or large-scale studies will succeed</td>
    </tr>
    <tr>
      <td>Many companies     in the <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> industries, including us, have     <font color="blue">suffered significant setbacks</font> in <font color="blue">clinical studies</font>, even after promising     results  had  been  obtained  in  <font color="blue">earlier studies</font></td>
    </tr>
    <tr>
      <td>We have stopped two     late-stage, Phase 3 <font color="blue">clinical studies</font> of product <font color="blue">candidates</font> following interim     analyses: a Phase 3 study of Pafase^® (rPAF-AH) for the treatment of severe     sepsis was stopped in 2002; and a study of LeukArrest^™ (rovelizumab) for     the treatment of <font color="blue">ischemic stroke</font> was stopped in 2000</td>
    </tr>
    <tr>
      <td>We anticipate that only some of our product <font color="blue">candidates</font> will show safety and     efficacy in <font color="blue">clinical studies</font> and many <font color="blue">may encounter <font color="blue">difficulties</font></font> or delays     during clinical <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Our efforts to obtain approval for <font color="blue">additional</font>     <font color="blue"><font color="blue">indication</font>s</font> for tadalafil are subject to many of the <font color="blue">same risks associated</font>     <font color="blue">with new products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Government </font><font color="blue"><font color="blue">regulatory</font> authorities may</font> not approve our product <font color="blue">candidates</font> or     may delay their approval</td>
    </tr>
    <tr>
      <td>Any failure to receive the <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> <font color="blue">necessary</font> to <font color="blue">commercialize</font>     our product <font color="blue">candidates</font> could severely harm our business</td>
    </tr>
    <tr>
      <td>Human <font color="blue">therapeutic</font>     products are subject to extensive and rigorous <font color="blue">government regulation</font></td>
    </tr>
    <tr>
      <td>For     example, the FDA regulates, among other things, the <font color="blue">development</font>, testing,     <font color="blue">manufacture</font>, safety, efficacy, record keeping, labeling, storage, approval,     advertising, promotion, sale and <font color="blue">distribution</font> of <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>Products <font color="blue">marketed abroad</font> are also subject to extensive <font color="blue">regulation by foreign</font>     <font color="blue">governments</font></td>
    </tr>
    <tr>
      <td>Except for Cialis, we have not had any <font color="blue">product candidate</font>     approved  for  sale  in any country</td>
    </tr>
    <tr>
      <td>In addition, we have only limited     experience in filing and pursuing <font color="blue">application</font>s <font color="blue">necessary</font> to <font color="blue">gain <font color="blue">regulatory</font></font>     approvals, which may impede our ability to obtain <font color="blue">such approvals</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">regulatory</font>  review and <font color="blue">approval process</font> is lengthy, expensive and     uncertain</td>
    </tr>
    <tr>
      <td>To secure FDA approval, we must submit extensive <font color="blue">manufacturing</font>,     preclinical and <font color="blue">clinical data</font> and supporting information to the FDA, for     each <font color="blue">indication</font> for which we are seeking approval, to establish the product     candidate’s safety and efficacy</td>
    </tr>
    <tr>
      <td>The <font color="blue">approval process</font> may take years to     complete and <font color="blue">may involve ongoing requirements</font> for post-marketing studies</td>
    </tr>
    <tr>
      <td>Any  FDA  or other <font color="blue"><font color="blue">regulatory</font> approval</font> of our product <font color="blue">candidates</font>, once     obtained, may be withdrawn</td>
    </tr>
    <tr>
      <td>The effect of <font color="blue">government regulation</font> may be to:           •   delay marketing <font color="blue">potential products</font> for a considerable period of time;           •   limit the <font color="blue">indicated uses</font> for which <font color="blue">potential products</font> may be marketed;           •   specify contra<font color="blue"><font color="blue">indication</font>s</font> or other <font color="blue">risk management requirements</font> that     may limit the use of our products;           •   <font color="blue">impose costly requirements on us as</font> a condition of approval or     <font color="blue">continued use</font> of our products; and           •   provide <font color="blue">competitive</font> advantage to other <font color="blue">pharmaceutical</font> and     <font color="blue"><font color="blue">bio<font color="blue">technology</font></font> companies</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">regulatory</font> compliance may prevent us from introducing new or     <font color="blue">improved products</font> or may require us to <font color="blue">stop marketing products</font></td>
    </tr>
    <tr>
      <td>If we fail     to <font color="blue">comply with</font> the laws and <font color="blue">regulations</font> pertaining to our business, we may     be subject to sanctions, including the temporary or <font color="blue">permanent suspension</font> of     <font color="blue">operations</font>, product recalls, marketing restrictions and civil and criminal     penalties</td>
    </tr>
    <tr>
      <td>17     ______________________________________________________________________    [37]Table of <font color="blue">Contents       </font>We may be unable to establish or maintain the <font color="blue">manufacturing</font> capabilities     <font color="blue">necessary</font> to develop and <font color="blue">commercialize</font> our <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>We do not currently have <font color="blue">facilities</font> to <font color="blue">manufacture</font> Cialis or our product     <font color="blue">candidates</font> in quantities <font color="blue">necessary</font> for <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>In addition, our     <font color="blue">manufacturing</font> capacity may be inadequate to complete all <font color="blue">clinical studies</font>     contemplated by us over time</td>
    </tr>
    <tr>
      <td>We intend to <font color="blue">rely significantly on contract</font>     <font color="blue">manufacture</font>rs, including <font color="blue">collaboration partners</font>, to produce large quantities     of drug material needed for <font color="blue">clinical studies</font> and <font color="blue">commercialization</font> of <font color="blue">Cialis  </font>   and our <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>Cialis is currently <font color="blue">manufacture</font>d by Lilly</td>
    </tr>
    <tr>
      <td>We     will have to depend on contract <font color="blue">manufacture</font>rs to deliver <font color="blue">materials on</font> a     <font color="blue">timely basis</font> and to <font color="blue">comply with</font> <font color="blue">regulatory</font> requirements, including Good     Manufacturing Practices, or GMP, <font color="blue">regulations</font> enforced by the FDA through its     <font color="blue">facilities</font> inspection program</td>
    </tr>
    <tr>
      <td>Contract <font color="blue">manufacture</font>rs may be unable to meet     our needs <font color="blue">with respect</font> to timing, quantity or quality of materials, and may     fail to satisfy applicable <font color="blue">regulatory</font> requirements <font color="blue">with respect</font> to the     <font color="blue">manufacture</font>  of  these  materials</td>
    </tr>
    <tr>
      <td>If we are unable to contract for a     <font color="blue">sufficient supply</font> of needed <font color="blue">materials on</font> acceptable terms, or if we should     <font color="blue">encounter delays</font> or <font color="blue">difficulties</font> in our <font color="blue">relationship</font>s with <font color="blue">manufacture</font>rs,     our revenues and potential <font color="blue">profitability</font> may be lower</td>
    </tr>
    <tr>
      <td>Our business may be harmed if we cannot obtain <font color="blue">sufficient quantities</font> of raw     materials and <font color="blue">process them reliably</font> and timely</td>
    </tr>
    <tr>
      <td>We  depend  on  others  for the <font color="blue">timely supply</font> of <font color="blue">raw <font color="blue">materials used</font></font> to     <font color="blue">manufacture</font> Cialis and to conduct pre<font color="blue">clinical testing</font> and <font color="blue">clinical studies</font>     of product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Once a supplier’s materials have been selected for     use in our <font color="blue">manufacturing</font> process, the supplier in effect becomes a sole or     limited source of that raw material due to <font color="blue">regulatory</font> compliance procedures</td>
    </tr>
    <tr>
      <td>Presently,  Lilly  is  the  sole  authorized  provider  of  the active     <font color="blue">pharmaceutical</font> ingredient (API) utilized in the <font color="blue">manufacture</font> of Cialis, and     all API production for Cialis is <font color="blue">conducted at</font> a single Lilly <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td><font color="blue">Lilly     </font><font color="blue">relies on</font> a third-party vendor which has the <font color="blue">exclusive rights</font> to mill the     API  to  conform  the  drug  substance  to  <font color="blue">specifications</font> used in the     <font color="blue">manufacturing</font> process</td>
    </tr>
    <tr>
      <td>Once milled, the refined API is shipped to various     Lilly locations, where the drug substance is <font color="blue">manufacture</font>d into tablets,     packaged  and  made  ready  for  sale</td>
    </tr>
    <tr>
      <td>At each of these stages in the     <font color="blue">manufacturing</font> process, <font color="blue">Lilly ICOS </font><font color="blue">depends on</font> an exclusive provider (ie,     Lilly  or  another vendor) for the <font color="blue">timely supply</font> and processing of raw     materials</td>
    </tr>
    <tr>
      <td>If any of these suppliers or processing <font color="blue">facilities</font> were to cease     production or <font color="blue">otherwise fail</font> to supply <font color="blue">Lilly ICOS </font><font color="blue">with raw materials</font> or     <font color="blue">manufacturing</font> services in a <font color="blue">timely manner</font>, <font color="blue">Lilly ICOS </font>and ICOS could be     <font color="blue">materially adversely affected</font></td>
    </tr>
    <tr>
      <td>Similar risks exist <font color="blue">with respect</font> to raw     <font color="blue">materials used</font> in testing and developing our other product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">adequately protect</font> our <font color="blue">intellectual property rights</font>, the     value <font color="blue">of Cialis </font>or of our <font color="blue">potential products</font> could be diminished</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> to a <font color="blue">significant extent on</font> our ability and the ability     of our <font color="blue">collaboration partners</font> to obtain, maintain and <font color="blue">enforce patents</font> and     other <font color="blue">proprietary rights</font></td>
    </tr>
    <tr>
      <td>Patent law relating to the scope of claims in the     <font color="blue">pharmaceutical</font>  and  <font color="blue">bio<font color="blue">technology</font></font> fields in which we operate is still     evolving and subject to a substantial degree of <font color="blue">uncertainty</font></td>
    </tr>
    <tr>
      <td>Accordingly,     there may be third-party patents or patent <font color="blue">application</font>s relevant to <font color="blue">Cialis  </font>   or our <font color="blue">potential products</font> that might block or <font color="blue">compete with</font> the <font color="blue">technologies</font>     and products <font color="blue">covered by</font> our patents or patent <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>We <font color="blue">also cannot</font>     be  certain that our pending patent <font color="blue">application</font>s will result in issued     patents or that others have not filed patent <font color="blue">application</font>s for <font color="blue">technology</font>     <font color="blue">covered by</font> our pending <font color="blue">application</font>s or that we were the first to invent the     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">third party</font> has filed a claim seeking to <font color="blue">add three individuals</font>     as co-inventors on two ICOS patents</td>
    </tr>
  </tbody>
</table>